SGT-210

About Sol-Gel Technologies

Sol-Gel Technologies' mission is to develop and commercialize advanced topical dermatological therapies using its patented Sol-Gel microencapsulation platform. Its key achievement is the FDA approval and launch of TWYNEO® for acne vulgaris, marking its transition to a commercial entity. The company's strategy combines proprietary development of its pipeline with strategic out-licensing to established dermatology players for commercialization. With a pipeline of 15 candidates targeting acne, rosacea, psoriasis, and other conditions, Sol-Gel aims to build a portfolio of differentiated products in the growing medical dermatology market.

Therapeutic Areas